HUP0204515A2 - 4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0204515A2 HUP0204515A2 HU0204515A HUP0204515A HUP0204515A2 HU P0204515 A2 HUP0204515 A2 HU P0204515A2 HU 0204515 A HU0204515 A HU 0204515A HU P0204515 A HUP0204515 A HU P0204515A HU P0204515 A2 HUP0204515 A2 HU P0204515A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- alkenyl
- alkyl
- optionally substituted
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical class NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 101150039148 NHX1 gene Proteins 0.000 abstract 1
- 201000005746 Pituitary adenoma Diseases 0.000 abstract 1
- 206010061538 Pituitary tumour benign Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 208000021310 pituitary gland adenoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek, racém, enantiomerformában, vagy ezek bármilyen kombinációjában, ahol a képletben R1jelentése lineáris vagy elágazó láncú 1-16 szénatomos alkil-,alkenil-, alkinil-, -(CH2)m-Y-Z11 vagy -(CH2)m-Z12 csoport, R2jelentése -C(Y)NHX1, -C(O)X2 vagy SO2X3 képletű csoport; R3 jelentésehidrogénatom, adott esetben szubsztituált alkil-, alkenil-, alkinil-,aralkilcsoport, adott esetben szubsztituált heteroarilalkilcsoportvagy -C(Y)-NHX11, -(CH2)n-C(O)X2, SO2X3 képletű csoport; X1 jelentéselineáris vagy elágazó láncú 1-15 szénatomos alkil-, alkenil-,alkinil-, -(CH2)m-Y-Z21, vagy -C(H2)pZ22 képletű csoport, X2 jelentéselineáris vagy elágazó láncú 1-10 szénatomos alkilcsoport,alkenilcsoport, amely adott esetben fenilcsoporttal van helyettesítve,ahol a fenilcsoport adott esetben önmagában is helyettesített lehet,alkinilcsoport vagy -(CH2)m,-W-(CH2)q-Z23 vagy -(CH2)p-U-Z24 képletűcsoport, X3 jelentése lineáris vagy elágazó láncú 1-10 szénatomosalkilcsoport, alkenilcsoport, amely adott esetben fenilcsoporttal vanhelyettesítve, ahol a fenilcsoport adott esetben önmagában ishelyettesített lehet, CF3 vagy -(CH2)pZ25 képletű csoport, Y jelentéseoxigénatom vagy kénatom; W jelentése oxigénatom vagy kénatom vagy SO2csoport; U jelentése kovalens kötés vagy oxigénatom; n értéke 0-4 egészszám; m értéke 1-6 egész szám; p jelentése 0-6 egész szám; q jelentése0-2 egész szám; vagy ezek gyógyászatilag elfogadható ásványi vagyszerves savakkal alkotott savaddíciós sói, azzal a megkötéssel, hogyaz (I) általános képletű vegyületekben R1 jelentése alkilcsoporttól,alkenilcsoporttól vagy benzilcsoporttól különböző; R2 csoportjelentése adott esetben szubsztituált benziloxicsoporttól különböző ésR3 jelentése aralkilcsoporttól különböző. A találmány tárgyát képezimég az (1) általános képletű vegyületek gyógyászati alkalmazása,elsősorban acromegalia, hipofízises adenoma vagy daganatok kezelésére. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9915724A FR2802206B1 (fr) | 1999-12-14 | 1999-12-14 | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
PCT/FR2000/003497 WO2001044191A1 (fr) | 1999-12-14 | 2000-12-13 | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0204515A2 true HUP0204515A2 (hu) | 2003-04-28 |
HUP0204515A3 HUP0204515A3 (en) | 2005-04-28 |
HU227838B1 HU227838B1 (en) | 2012-05-02 |
Family
ID=9553215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0204515A HU227838B1 (en) | 1999-12-14 | 2000-12-13 | 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use |
Country Status (23)
Country | Link |
---|---|
US (4) | US7115634B2 (hu) |
EP (1) | EP1286966B1 (hu) |
JP (2) | JP4838474B2 (hu) |
KR (2) | KR20070014235A (hu) |
CN (1) | CN1207283C (hu) |
AR (1) | AR034244A1 (hu) |
AT (1) | ATE401308T1 (hu) |
AU (1) | AU779341B2 (hu) |
CA (1) | CA2394086C (hu) |
CY (1) | CY1108415T1 (hu) |
CZ (1) | CZ305360B6 (hu) |
DE (1) | DE60039539D1 (hu) |
DK (1) | DK1286966T3 (hu) |
ES (1) | ES2310529T3 (hu) |
FR (1) | FR2802206B1 (hu) |
HK (1) | HK1054029A1 (hu) |
HU (1) | HU227838B1 (hu) |
MY (1) | MY126973A (hu) |
NZ (1) | NZ520071A (hu) |
PL (1) | PL204864B1 (hu) |
PT (1) | PT1286966E (hu) |
RU (1) | RU2266282C2 (hu) |
WO (1) | WO2001044191A1 (hu) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
RU2398765C1 (ru) | 2000-03-06 | 2010-09-10 | Акадиа Фармасьютикалз, Инк. | Азациклические соединения для применения при лечении опосредованных серотонином заболеваний |
EP1311502A1 (en) * | 2000-08-17 | 2003-05-21 | Celltech R&D Limited | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders |
US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
CN1780621A (zh) * | 2001-08-03 | 2006-05-31 | 先灵公司 | 作为γ分泌酶抑制剂的磺酰胺衍生物 |
ATE450508T1 (de) * | 2001-09-14 | 2009-12-15 | High Point Pharmaceuticals Llc | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren |
US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
DE60237528D1 (de) | 2001-09-14 | 2010-10-14 | High Point Pharmaceuticals Llc | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative |
US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
CN100462359C (zh) * | 2001-11-28 | 2009-02-18 | 科学研究和应用咨询公司 | 5-硫烷基-4h-1,2,4-***衍生物及其作为药物的应用 |
FR2832710B1 (fr) * | 2001-11-28 | 2004-09-03 | Sod Conseils Rech Applic | Derives de 5-sulfanyl-4h-1,2,4-triazoles et leur utilisation en tant que medicaments |
NZ533567A (en) | 2001-12-28 | 2007-06-29 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
JP4597524B2 (ja) * | 2002-02-01 | 2010-12-15 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | アミノアルキル置換されたアゼチジン、ピロリジン、ピペリジン、およびアゼパンのアミド |
US7101898B2 (en) | 2002-02-01 | 2006-09-05 | Novo Nordisk A/S | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004000808A2 (en) * | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
TW200409637A (en) | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
WO2004009549A2 (en) * | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
GB0314054D0 (en) * | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
SI1638933T1 (sl) * | 2003-06-17 | 2008-10-31 | Pfizer | Derivati N-pirolidin-3-il-amida kot inhibitorji ponovnega privzema serotonina in noradrenalina |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
CN101048393A (zh) | 2004-06-30 | 2007-10-03 | 先灵公司 | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 |
JP5154227B2 (ja) | 2004-09-27 | 2013-02-27 | アカディア ファーマシューティカルズ インコーポレイテッド | N−(4−フルオロベンジル)−n−(1−メチルピペリジン−4−イル)−n’−(4−(2−メチルプロピルオキシ)フェニルメチル)カルバミドの塩及びその調製 |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
CA2601777A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
CN101189226A (zh) | 2005-06-02 | 2008-05-28 | 霍夫曼-拉罗奇有限公司 | 哌啶-4-基-酰胺衍生物及它们作为sst受体亚型5拮抗剂的应用 |
US8501739B2 (en) * | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
KR20090040259A (ko) * | 2006-05-29 | 2009-04-23 | 하이 포인트 파마슈티칼스, 엘엘씨 | 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 h3 수용체 안타고니스트로서의 용도 |
US7674804B2 (en) | 2006-06-29 | 2010-03-09 | Hoffmann-La Roche Inc. | Pyrimidine and quinazoline derivatives as SST5 modulators |
JP2010522198A (ja) | 2007-03-19 | 2010-07-01 | アカドイア プハルマセウチカルス インコーポレーテッド | 5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用 |
WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
EP2014656A3 (en) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
US20090082388A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
EP2060564A1 (en) * | 2007-11-19 | 2009-05-20 | Ludwig-Maximilians-Universität München | Non-peptidic promoters of apoptosis |
EP2282735B1 (en) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
ES2352398B1 (es) | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciencia I Tecnologia S.A. | N-fenetilsulfonamidas-n-sustituidas para la identificacion de actividad biologica y farmacologica. |
JP6496549B2 (ja) * | 2011-11-30 | 2019-04-03 | サレプタ セラピューティクス, インコーポレイテッド | 脊髄性筋萎縮症における誘発されたエクソン包含 |
ES2832531T3 (es) | 2011-11-30 | 2021-06-10 | Sarepta Therapeutics Inc | Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones |
EP2871179A4 (en) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
JP2016516804A (ja) * | 2013-04-17 | 2016-06-09 | ファイザー・インク | 心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体 |
WO2015046482A1 (ja) * | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
KR101541647B1 (ko) | 2014-04-24 | 2015-08-03 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
SI3325444T1 (sl) | 2015-07-20 | 2021-11-30 | Acadia Pharmaceuticals Inc. | Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C |
JP6987041B2 (ja) | 2015-08-28 | 2021-12-22 | サレプタ セラピューティクス,インコーポレイテッド | 脊髄性筋萎縮症におけるエクソン包含のための修飾アンチセンスオリゴマー |
WO2017049295A1 (en) | 2015-09-18 | 2017-03-23 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
EP3484865B1 (en) | 2016-07-14 | 2022-09-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
EA201992083A1 (ru) * | 2017-03-16 | 2020-03-18 | Кринетикс Фармасьютикалс, Инк. | Модуляторы соматостатина и их применения |
WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
SG11202001062XA (en) | 2017-08-21 | 2020-03-30 | Acadia Pharm Inc | Compounds, salts thereof and methods for treatment of diseases |
US11440884B2 (en) | 2017-08-21 | 2022-09-13 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and methods for treatment of diseases |
EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
IL276029B1 (en) | 2018-01-17 | 2024-03-01 | Crinetics Pharmaceuticals Inc | A process for preparing somatostatin modulators |
MA51840A (fr) | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
US10696689B2 (en) | 2018-09-18 | 2020-06-30 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
CN114585614A (zh) | 2019-08-14 | 2022-06-03 | 克林提克斯医药股份有限公司 | 非肽促生长素抑制素5型受体激动剂及其用途 |
US11655235B2 (en) | 2019-11-06 | 2023-05-23 | Yuhan Corporation | Pyrrolidine and piperidine compounds |
US20230348421A1 (en) * | 2020-07-22 | 2023-11-02 | Geneora Pharma (Shijiazhuang) Co., Ltd. | 5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof |
KR20230066379A (ko) | 2020-09-09 | 2023-05-15 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 제형 |
CA3207378A1 (en) | 2021-02-17 | 2022-08-25 | Yuxin Zhao | Crystalline forms of a somatostatin modulator |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1425354A (en) * | 1973-10-10 | 1976-02-18 | Wyeth John & Brother Ltd | Indole derivatives |
GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
JPS5152176A (hu) * | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
JPS5285174A (en) * | 1976-01-05 | 1977-07-15 | Yoshitomi Pharmaceut Ind Ltd | Novel urea or thiourea derivatives |
GB1574418A (en) * | 1976-11-16 | 1980-09-03 | Anphar Sa | Piperidine derivatives |
US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
AU1285499A (en) * | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
JP2002501898A (ja) * | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
DE60023492T2 (de) * | 1999-05-17 | 2006-07-20 | Novo Nordisk A/S | Glucagon antagonisten/inverse agonisten |
US6344358B1 (en) | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
RU2398765C1 (ru) * | 2000-03-06 | 2010-09-10 | Акадиа Фармасьютикалз, Инк. | Азациклические соединения для применения при лечении опосредованных серотонином заболеваний |
-
1999
- 1999-12-14 FR FR9915724A patent/FR2802206B1/fr not_active Expired - Lifetime
-
2000
- 2000-12-13 ES ES00993405T patent/ES2310529T3/es not_active Expired - Lifetime
- 2000-12-13 RU RU2002118705/04A patent/RU2266282C2/ru active
- 2000-12-13 HU HU0204515A patent/HU227838B1/hu unknown
- 2000-12-13 DE DE60039539T patent/DE60039539D1/de not_active Expired - Lifetime
- 2000-12-13 NZ NZ520071A patent/NZ520071A/xx not_active IP Right Cessation
- 2000-12-13 EP EP00993405A patent/EP1286966B1/fr not_active Expired - Lifetime
- 2000-12-13 CZ CZ2002-2060A patent/CZ305360B6/cs not_active IP Right Cessation
- 2000-12-13 AU AU28560/01A patent/AU779341B2/en not_active Expired
- 2000-12-13 CN CNB008171777A patent/CN1207283C/zh not_active Expired - Lifetime
- 2000-12-13 KR KR1020077001118A patent/KR20070014235A/ko not_active Application Discontinuation
- 2000-12-13 DK DK00993405T patent/DK1286966T3/da active
- 2000-12-13 US US10/130,924 patent/US7115634B2/en not_active Expired - Lifetime
- 2000-12-13 PL PL356365A patent/PL204864B1/pl unknown
- 2000-12-13 KR KR1020027007506A patent/KR100725190B1/ko active IP Right Grant
- 2000-12-13 CA CA2394086A patent/CA2394086C/fr not_active Expired - Lifetime
- 2000-12-13 WO PCT/FR2000/003497 patent/WO2001044191A1/fr active IP Right Grant
- 2000-12-13 PT PT00993405T patent/PT1286966E/pt unknown
- 2000-12-13 JP JP2001544681A patent/JP4838474B2/ja not_active Expired - Lifetime
- 2000-12-13 MY MYPI20005862A patent/MY126973A/en unknown
- 2000-12-13 AT AT00993405T patent/ATE401308T1/de active
- 2000-12-14 AR ARP000106648A patent/AR034244A1/es active IP Right Grant
-
2003
- 2003-09-03 HK HK03106281.2A patent/HK1054029A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 US US11/122,293 patent/US7393861B2/en not_active Expired - Lifetime
-
2008
- 2008-05-02 US US12/151,115 patent/US7858789B2/en not_active Expired - Fee Related
- 2008-10-14 CY CY20081101138T patent/CY1108415T1/el unknown
-
2010
- 2010-11-15 US US12/946,504 patent/US8110574B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 JP JP2011024405A patent/JP2011121982A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0204515A2 (hu) | 4-Aminopiperidin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
MY138941A (en) | Aryl-pyridine derivatives | |
HUP0401837A2 (hu) | Dikarbonsavszármazékok, előállításuk és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
TW200519088A (en) | Aryl or heteroaryl amide compounds | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
PE58699A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
TW200635585A (en) | Monocyclic substituted methanones | |
ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
RS87204A (en) | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | |
RU2008136769A (ru) | Аминоацильные производные пролекарства и лекарственные средства для лечения тромбоэмболических заболеваний | |
HUP0202414A2 (hu) | Új eljárás perindopril és analógjai, és ezek sói előállítására | |
MXPA03000547A (es) | Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares. | |
HUP0203471A2 (hu) | Trombózisellenes hatású vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE104292T1 (de) | Verbindungen fuer die induktion der in vitround in vivo-erzeugung von cytokinen. | |
HU0104272D0 (en) | New cyclobutendione compounds a process for their preparation and pharmaceutical compositions containing them | |
LV10235A (lv) | Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode | |
DK0732332T3 (da) | Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf | |
RU2010104475A (ru) | Аминоацильные пролекарства в качестве фармацевтически действующих веществ для лечения тромбоэмболических заболеваний | |
ATE116647T1 (de) | Thiophenderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
TW273553B (hu) | ||
HUP0203383A2 (hu) | Aminofenoxiacetamid-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
HUP0102447A2 (hu) | Új oktahidro-6,10-dioxo-6H-piridazino[1,2-a][1,2]diazepin-1-karbonsav-származékok, eljárás a vegyületek előállítására és alkalmazásuk gyógyászati hatóanyagok előállítására | |
HUP0103113A2 (hu) | NOS inhibitorokat tartalmazó gyógyászati készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: IPSEN PHARMA S.A.S., FR Free format text: FORMER OWNER(S): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.), FR |